AstraZeneca to acquire EsoBiotec for $1bn.

AstraZeneca, a global, science-led biopharmaceutical business, agreed to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, for $1bn. "We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform. We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy," Susan Galbraith, AstraZeneca Executive Vice President, Oncology Haematology R&D.